Cargando…

Comprehensive optimization of urinary exfoliated tumor cells tests in bladder cancer with a promising microfluidic platform

BACKGROUND: Enrichment of urinary exfoliated tumor cells (UETCs) is a noninvasive way of bladder cancer diagnosis, but the lack of specific capture and identification of tumor cells from the urine remains a limitation that impedes the development of liquid biopsy. METHODS: The CytoBot(®) 2000, a nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Fengbin, Wang, Jie, Yu, Yanlan, Yan, Jing, Ding, Guoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067033/
https://www.ncbi.nlm.nih.gov/pubmed/36567509
http://dx.doi.org/10.1002/cam4.5481
_version_ 1785018379443109888
author Gao, Fengbin
Wang, Jie
Yu, Yanlan
Yan, Jing
Ding, Guoqing
author_facet Gao, Fengbin
Wang, Jie
Yu, Yanlan
Yan, Jing
Ding, Guoqing
author_sort Gao, Fengbin
collection PubMed
description BACKGROUND: Enrichment of urinary exfoliated tumor cells (UETCs) is a noninvasive way of bladder cancer diagnosis, but the lack of specific capture and identification of tumor cells from the urine remains a limitation that impedes the development of liquid biopsy. METHODS: The CytoBot(®) 2000, a novel circulating cell isolation and enrichment platform, was used for UETCs isolation after comprehensive optimization. The commercial cell lines of bladder cancer were used in spiking assay for cell recovery test. The flow cytometry and immunofluorescent staining assays were performed for expression validation of capture target and identification markers. The performance of optimized platform was validated by 159 clinical samples and analyzed using receiver operator characteristic curve. RESULTS: The chip that had a pore diameter of 15*20 μm could reduce the background residues while maintaining a higher cell recovery rate. We found that the cell capture ability of chip significantly improved after anti‐EpCam antibody encapsulation, but not with T4L6FM1. In identification system optimization, the spiking assay and validation of clinical sample showed that the performance of CK20 and DBC‐1 were better that pan‐CK in tumor cell identification, in addition, the staining quality is more legible with CK20. CONCLUSION: The optimized capture chip is more specific for UETCs isolation. CK20 and DBC‐1 are both sensitive biomarkers of UETCs in bladder cancer diagnosis. The performance of this optimized platform is excellent in clinical test that improves the accuracy of urine cell testing and provides a new alternative for the clinical application of BLCA liquid biopsy assessment.
format Online
Article
Text
id pubmed-10067033
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100670332023-04-03 Comprehensive optimization of urinary exfoliated tumor cells tests in bladder cancer with a promising microfluidic platform Gao, Fengbin Wang, Jie Yu, Yanlan Yan, Jing Ding, Guoqing Cancer Med RESEARCH ARTICLES BACKGROUND: Enrichment of urinary exfoliated tumor cells (UETCs) is a noninvasive way of bladder cancer diagnosis, but the lack of specific capture and identification of tumor cells from the urine remains a limitation that impedes the development of liquid biopsy. METHODS: The CytoBot(®) 2000, a novel circulating cell isolation and enrichment platform, was used for UETCs isolation after comprehensive optimization. The commercial cell lines of bladder cancer were used in spiking assay for cell recovery test. The flow cytometry and immunofluorescent staining assays were performed for expression validation of capture target and identification markers. The performance of optimized platform was validated by 159 clinical samples and analyzed using receiver operator characteristic curve. RESULTS: The chip that had a pore diameter of 15*20 μm could reduce the background residues while maintaining a higher cell recovery rate. We found that the cell capture ability of chip significantly improved after anti‐EpCam antibody encapsulation, but not with T4L6FM1. In identification system optimization, the spiking assay and validation of clinical sample showed that the performance of CK20 and DBC‐1 were better that pan‐CK in tumor cell identification, in addition, the staining quality is more legible with CK20. CONCLUSION: The optimized capture chip is more specific for UETCs isolation. CK20 and DBC‐1 are both sensitive biomarkers of UETCs in bladder cancer diagnosis. The performance of this optimized platform is excellent in clinical test that improves the accuracy of urine cell testing and provides a new alternative for the clinical application of BLCA liquid biopsy assessment. John Wiley and Sons Inc. 2022-12-25 /pmc/articles/PMC10067033/ /pubmed/36567509 http://dx.doi.org/10.1002/cam4.5481 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Gao, Fengbin
Wang, Jie
Yu, Yanlan
Yan, Jing
Ding, Guoqing
Comprehensive optimization of urinary exfoliated tumor cells tests in bladder cancer with a promising microfluidic platform
title Comprehensive optimization of urinary exfoliated tumor cells tests in bladder cancer with a promising microfluidic platform
title_full Comprehensive optimization of urinary exfoliated tumor cells tests in bladder cancer with a promising microfluidic platform
title_fullStr Comprehensive optimization of urinary exfoliated tumor cells tests in bladder cancer with a promising microfluidic platform
title_full_unstemmed Comprehensive optimization of urinary exfoliated tumor cells tests in bladder cancer with a promising microfluidic platform
title_short Comprehensive optimization of urinary exfoliated tumor cells tests in bladder cancer with a promising microfluidic platform
title_sort comprehensive optimization of urinary exfoliated tumor cells tests in bladder cancer with a promising microfluidic platform
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067033/
https://www.ncbi.nlm.nih.gov/pubmed/36567509
http://dx.doi.org/10.1002/cam4.5481
work_keys_str_mv AT gaofengbin comprehensiveoptimizationofurinaryexfoliatedtumorcellstestsinbladdercancerwithapromisingmicrofluidicplatform
AT wangjie comprehensiveoptimizationofurinaryexfoliatedtumorcellstestsinbladdercancerwithapromisingmicrofluidicplatform
AT yuyanlan comprehensiveoptimizationofurinaryexfoliatedtumorcellstestsinbladdercancerwithapromisingmicrofluidicplatform
AT yanjing comprehensiveoptimizationofurinaryexfoliatedtumorcellstestsinbladdercancerwithapromisingmicrofluidicplatform
AT dingguoqing comprehensiveoptimizationofurinaryexfoliatedtumorcellstestsinbladdercancerwithapromisingmicrofluidicplatform